BOD1

Across TCGA pan-cancer cohorts, BOD1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated BOD1 data layer compared with 28 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher BOD1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated BOD1 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

CCRCC, HNSC, and UCEC are the cancer types where BOD1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.346	0.782	<.001	67	view →
HNSC	DFS	Median	All	0.515	0.739	.008	11	view →
UCEC	OS	Tertile	II,III,IV	0.584	1.000	.025	4	view →
PDAC	OS	Quartile	III,IV	1.000	0.500	.040	2	view →
LSCC	DFS	Median	All	0.498	0.828	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

BOD1–CCRCC (DFS)

Open the CCRCC breakdown →